Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Open accessThe DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background: The number of obese people continues to increase worldwide, and obesity-related complications add to every country's health burden. Consequently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), are attracting increasing attention. This study sought to assess the cost effectiveness for weight loss of 4 GLP-1RAs in adult patients with obesity in the United States. Methods: Four GLP-1RA groups that received Liraglutide (1.8 mg QD), Semaglutide (1.0 mg QW), Dulaglutide (1.5 mg QW), or Exenatide (10 μg BID), and one no-treatment group were compared using a decision-tree model. All the estimated parameters were derived from published articles. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) were adopted as the study endpoints. We analyzed the results with the willingness-to-pay (WTP) threshold, and conducted deterministic and probabilistic sensitivity analyses. Results: The GLP-1RAs produced effective weight-loss results; however, not all the GLP-1RAs were cost effective compared to no treatment based on a WTP threshold of $195000/QALY. Among the 4 GLP-1RAs, Semaglutide provided a cost-effective strategy with an ICER of $135467/QALY. The sensitivity analyses showed that these results are reliable. Conclusions: Among the 4 GLP-1RAs, Semaglutide was the most cost-effective obesity medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In short term analyses (∼1/2 year) evaluating quality adjusted life years (QALYs) and incremental cost effectiveness ratios (ICERs), semaglutide was the most cost-effective compared to exenatide, dulaglutide, liraglutide or no treatment82 (Fig. 2).”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [82]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · cited 1×
“Conversely, pharmacotherapy is a non-invasive approach that can help people with obesity to adhere to weight-loss strategies, improve their quality of life, and reduce the risk of comorbidities (6).”
BackgroundThe Public Health Impact of Obesity
Visscher, T. L., & Seidell, J. C. (2001) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.22.1.355 · Cited by 1,008 · cited 1×
“A 5% weight loss in obese patients can improve their health and reduce the incidence of obesity-related complications (4).”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Glucagonlike peptide-1 receptor agonists (GLP-1RAs) are a class of therapeutic agents that provide significant improvements in Hemoglobin A1c (HbA1c), and also promote weight loss and carry a low risk of hypoglycemia (7-9).”
Backgroundon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
The Global Burden of Obesity and the Challenges of Prevention
Seidell, J. C., & Halberstadt, J. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000375143 · Cited by 786 · cited 1×
“An estimated 650 million adults are overweight or obese, and the number of obese people continues to increase worldwide (1).”
BackgroundPratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · cited 1×
“Additionally, Semaglutide is currently available in oral formulation, and the effect and price are similar to the injection formulation (30).”
BackgroundHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 416 · cited 2×
“A number of studies have evaluated the cost effectiveness of GLP-1RAs in the treatment of diabetes, and the efficiency parameter is mostly HbA1c, but only a few studies have evaluated their weight-loss efficacy (15).”
BackgroundWysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376 · cited 1×
“21037/atm-22-200 efficiency data were obtained from randomized, placebocontrolled clinical trials (18-21).”
Xu, H., Cupples, L. A., Stokes, A., & Liu, C.-T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.4587 · Cited by 182 · cited 1×
“In the United States (US), overweight or obesity rates have increased threefold in the last 40 years (2).”
BackgroundAnti-diabetic drugs and weight loss in patients with type 2 diabetes
Lazzaroni, E., Ben Nasr, M., Loretelli, C., Pastore, I., Plebani, L., Lunati, M. E., Vallone, L., Bolla, A. M., Rossi, A., Montefusco, L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105782 · Cited by 182 · cited 1×
“However, the efficacy of both medications in terms of weight loss has been shown, and they are increasingly being used clinically (11-14).”
BackgroundSaunders, K. H., Umashanker, D., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.010 · Cited by 159 · cited 1×
“However, these measures further trigger the body’s adaptive physiological responses, leading to increased appetite and a lower resting metabolic rate (5).”
BackgroundWeinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149 · cited 1×
“Moreover, many studies have found that a plateau or weight re-gain occurs after about 40 weeks (31,32).”
BackgroundEffects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127 · cited 1×
“21037/atm-22-200 efficiency data were obtained from randomized, placebocontrolled clinical trials (18-21).”
Young adult weight trajectories through midlife by body mass category
Malhotra, R., Østbye, T., Riley, C. M., & Finkelstein, E. A. (2013) · Obesity · doi:10.1002/oby.20318 · Cited by 115
Lewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., et al. (2019) · Obesity · doi:10.1002/oby.22430 · Cited by 110 · cited 1×
“21037/atm-22-200 choice for cardiovascular disease patients because of its adverse effects even if it has a better curative effect (25).”
BackgroundSun, F., Chai, S., Li, L., Yu, K., Yang, Z., Wu, S., Zhang, Y., Ji, L., & Zhan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/157201 · Cited by 101
Self-citationEffects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Monami, M., Dicembrini, I., Marchionni, N., Rotella, C. M., & Mannucci, E. (2012) · Experimental Diabetes Research · doi:10.1155/2012/672658 · Cited by 99 · cited 1×
“Glucagonlike peptide-1 receptor agonists (GLP-1RAs) are a class of therapeutic agents that provide significant improvements in Hemoglobin A1c (HbA1c), and also promote weight loss and carry a low risk of hypoglycemia (7-9).”
BackgroundSiskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13167 · Cited by 98 · cited 1×
“21037/atm-22-200 several weight-loss programs have shown the effect of Exenatide on weight loss in individuals with hypothalamic obesity and clozapine-associated obesity (28,29).”
BackgroundElkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96 · cited 1×
“, GLP-1RAs have produced positive results in individuals with polycystic ovary syndrome) (26,27).”
BackgroundCost-effectiveness of Bariatric Surgery in Adolescents With Obesity
Klebanoff, M. J., Chhatwal, J., Nudel, J. D., Corey, K. E., Kaplan, L. M., & Hur, C. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.3640 · Cited by 92 · cited 1×
“TreeAge Pro is a software platform that is used to build and analyze state-transition models, which are useful for assessing the effect of treatments, including their cost effectiveness (16).”
MethodRoth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87 · cited 1×
“21037/atm-22-200 several weight-loss programs have shown the effect of Exenatide on weight loss in individuals with hypothalamic obesity and clozapine-associated obesity (28,29).”
BackgroundThe public health impact of obesity
Visscher, T. L. S. (2001) · doi:10.18174/197626 · Cited by 75
Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14465 · Cited by 67 · cited 1×
“However, the efficacy of both medications in terms of weight loss has been shown, and they are increasingly being used clinically (11-14).”
BackgroundTaylor, K., Gurney, K., Han, J., Pencek, R., Walsh, B., & Trautmann, M. (2011) · BMC Endocrine Disorders · doi:10.1186/1472-6823-11-9 · Cited by 64 · cited 1×
“However, the efficacy of both medications in terms of weight loss has been shown, and they are increasingly being used clinically (11-14).”
BackgroundThe cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020) · Obesity Science & Practice · doi:10.1002/osp4.390 · Cited by 61 · cited 1×
“Currently, very few weight-loss drugs have been approved for use by the FDA, other than Lorcaserin and Orlistat, which have relatively modest clinical efficacy and have not been widely used in clinical practice or well known to the public (24).”
BackgroundBhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 58
Henry, R. R., Klein, E. J., Han, J., & Iqbal, N. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0107 · Cited by 45 · cited 1×
“Moreover, many studies have found that a plateau or weight re-gain occurs after about 40 weeks (31,32).”
BackgroundHansen, B. B., Nuhoho, S., Ali, S. N., Dang-Tan, T., Valentine, W. J., Malkin, S. J. P., & Hunt, B. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1722678 · Cited by 36 · cited 2×
“The cost of the injection needle used was also based on the previous literature (22).”
MethodCost-Effectiveness Analysis of Qsymia for Weight Loss
Finkelstein, E. A., Kruger, E., & Karnawat, S. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0182-6 · Cited by 34 · cited 1×
“For all the medication groups, the cost of 2 doctor visits ($178) before the patients started taking the weight-loss medications was added (23).”
BackgroundNowrouzi‐Sohrabi, P., Rezaei, S., Jalali, M., Ashourpour, M., Ahmadipour, A., Keshavarz, P., & Akbari, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173823 · Cited by 24 · cited 1×
“, GLP-1RAs have produced positive results in individuals with polycystic ovary syndrome) (26,27).”
BackgroundTham, L. S., Pantalone, K. M., Dungan, K. M., Munir, K. M., Tang, C. C., Кониг, М., & Kwan, A. Y. M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14582 · Cited by 16 · cited 1×
“However, the efficacy of both medications in terms of weight loss has been shown, and they are increasingly being used clinically (11-14).”
BackgroundCost-effectiveness of Bariatric Surgery for People with Morbid Obesity in South Korea
An, S., Park, H., Oh, S.-H., Heo, Y., Park, S., Jeon, S. M., & Kwon, J. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04122-w · Cited by 14 · cited 2×
“Obesity is a risk factor for chronic diseases, including hypertension, diabetes, and cardiovascular diseases, and is also an independent risk factor for mortality (3).”
Background
Cited by
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“In short term analyses ( ∼ 1/2 year) evaluating quality adjusted life years (QALYs) and incremental cost effectiveness ratios (ICERs), semaglutide was the most cost-effective compared to exenatide, dulaglutide, liraglutide or no treatment 82 (Fig.”
BackgroundThe psychophysiology of anxiety.
LADER, M. H. (1983) · PubMed · Cited by 133
Semaglutide vs endoscopic sleeve gastroplasty for weight loss
Haseeb, M., Chhatwal, J., Xiao, J., Jirapinyo, P., & Thompson, C. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6221 · Cited by 73
Cohen, R. V., Busetto, L., Levinson, R., Le Roux, C. W., Salminen, P., Prager, G., Surgery, I. C. O. T. R. O. O. M. M. I. T. C. O. M. B., Aminian, A., Blüher, M., Carlsson, L., et al. (2024) · British Journal of Surgery · doi:10.1093/bjs/znae283 · Cited by 52
Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14940 · Cited by 40
“A recent study attempted to calculate quality-adjusted life years indirectly for glucagon-like peptide-1 agonists based on existing data and found that semaglutide was the most costeffective of the drugs tested.(16) Tirzepatide is first in a new drug class that also induces clinically relevant weight reduction.”
Background
Metadata
- Authors
- Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P.
- Affiliations
- Zhejiang Provincial People's Hospital (CN)
- Corresponding author
- Huang, Ping
- ORCID
- Huang, Ping
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2022-02
- Volume
- 10
- Issue
- 3
- Pages
- 152-152
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- PMC
- PMC8904982
- OpenAlex
- W4212785398
- Semantic Scholar
- bbfa8cf3066ae7519753db8df3c2cc1fd8ba6ed2
- Cited by
- 45
- References
- 35
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 9 · 2023: 7 · 2022: 3
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82003189)
- Zhejiang Pharmaceutical Association
- Natural Science Foundation of Zhejiang Province (LQ17H310002, No. LQ17H310002, LYY19H310009, LYY21H310011)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity, GLP-1 receptor agonists, anti-obesity drugs, cost-effectiveness, semaglutide, liraglutide, dulaglutide, exenatide, quality-adjusted life years, incremental cost-effectiveness ratio, willingness-to-pay threshold, decision tree
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.